[go: up one dir, main page]

UY30987A1 - 3-IMIDAZOLIL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES - Google Patents

3-IMIDAZOLIL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES

Info

Publication number
UY30987A1
UY30987A1 UY30987A UY30987A UY30987A1 UY 30987 A1 UY30987 A1 UY 30987A1 UY 30987 A UY30987 A UY 30987A UY 30987 A UY30987 A UY 30987A UY 30987 A1 UY30987 A1 UY 30987A1
Authority
UY
Uruguay
Prior art keywords
treatment
proliferative diseases
imidazolil
indoles
variants
Prior art date
Application number
UY30987A
Other languages
Spanish (es)
Inventor
Andrea Vaupel
Lorenz Mayr
Keiichi Masuya
Joanna Hergovich Lisztwan
Joanna Hergovich
Jierg Kallen
Jean-Marc Groell
Pascal Furet
Nicole Buschmann
Andreas Boettcher
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38328915&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY30987(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of UY30987A1 publication Critical patent/UY30987A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invencion se refiere a compuestos de 3-heterociclil-indolilo capaces de inhibir la interaccion entre p53, o variantes del mismo, y MDM2 y/o MDM4, o variantes de los mismos, respectivamente, teniendo estos compuestos la formual I: en donde R1, R2, R3, R4, RA, e Y son como se definen en la memoria descriptiva. Debido a su actividad, los compuestos son utiles en el tratamiento de diferentes trastornos y enfermedades mediadas por la actividad de MDM2 y/o MDM4, o variantes de los mismos, tales como enfermedades inflamatorias y proliferativas, o en la proteccion de las células.The invention relates to 3-heterocyclyl-indolyl compounds capable of inhibiting the interaction between p53, or variants thereof, and MDM2 and / or MDM4, or variants thereof, respectively, these compounds having the form I: wherein R1 , R2, R3, R4, RA, and Y are as defined in the specification. Due to their activity, the compounds are useful in the treatment of different disorders and diseases mediated by the activity of MDM2 and / or MDM4, or variants thereof, such as inflammatory and proliferative diseases, or in the protection of cells.

UY30987A 2007-03-29 2008-03-28 3-IMIDAZOLIL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES UY30987A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07105269 2007-03-29

Publications (1)

Publication Number Publication Date
UY30987A1 true UY30987A1 (en) 2008-10-31

Family

ID=38328915

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30987A UY30987A1 (en) 2007-03-29 2008-03-28 3-IMIDAZOLIL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES

Country Status (27)

Country Link
US (1) US8053457B2 (en)
EP (1) EP2142535A2 (en)
JP (1) JP2010522723A (en)
KR (1) KR20090122403A (en)
CN (1) CN101679382A (en)
AR (1) AR065860A1 (en)
AU (1) AU2008234954B9 (en)
BR (1) BRPI0810082A2 (en)
CA (1) CA2682483A1 (en)
CL (1) CL2008000899A1 (en)
CR (1) CR11019A (en)
DO (1) DOP2009000229A (en)
EA (1) EA200901212A1 (en)
EC (1) ECSP099660A (en)
GT (1) GT200900256A (en)
IL (1) IL200862A0 (en)
MA (1) MA31260B1 (en)
MX (1) MX2009010413A (en)
NI (1) NI200900177A (en)
PA (1) PA8774001A1 (en)
PE (1) PE20081897A1 (en)
SM (1) SMP200900085B (en)
TN (1) TN2009000388A1 (en)
TW (1) TW200843746A (en)
UY (1) UY30987A1 (en)
WO (1) WO2008119741A2 (en)
ZA (1) ZA200906210B (en)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007235578B2 (en) * 2006-04-07 2011-07-14 Janssen Pharmaceutica N.V. Indoles and benzoimidazoles as modulators of the histamine H4 receptor
AR070398A1 (en) 2008-02-22 2010-03-31 Gruenenthal Chemie INDOL SUBSTITUTED DERIVATIVES
US20100035862A1 (en) * 2008-06-25 2010-02-11 Abbott Laboratories Novel aza-cyclic indole-2-carboxamides and methods of use thereof
MX353900B (en) 2008-11-07 2018-02-01 Massachusetts Inst Technology Aminoalcohol lipidoids and uses thereof.
CN102356085A (en) * 2009-01-16 2012-02-15 第一三共株式会社 Imidazothiazole derivative having proline ring structure
JP2012102017A (en) * 2009-03-03 2012-05-31 Astellas Pharma Inc Indole compound
US20120028990A1 (en) * 2009-04-16 2012-02-02 Msd K.K 3 aryl or heteroaryl-substituted indole derivative
AU2010319595B2 (en) 2009-11-12 2015-09-17 The Regents Of The University Of Michigan Spiro-oxindole MDM2 antagonists
WO2011106650A2 (en) * 2010-02-27 2011-09-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Novel p53-mdm2/p53-mdm4 antagonists to treat proliferative disease
JO2998B1 (en) * 2010-06-04 2016-09-05 Amgen Inc Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer
AU2011299551A1 (en) * 2010-09-08 2013-03-21 University Of Pittsburgh - Of The Commonwealth System Of Higher Education P53-Mdm2 antagonists
FR2967072B1 (en) 2010-11-05 2013-03-29 Univ Dundee PROCESS FOR IMPROVING INFLUENZA PRODUCTION OF VACCINE AND SEEDS
JP2014500870A (en) 2010-11-12 2014-01-16 ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、ミシガン Spiro-oxindole MDM2 antagonist
US20120202794A1 (en) * 2011-01-24 2012-08-09 Pharmasset, Inc. Compounds
CA2829188C (en) 2011-03-10 2016-10-18 Daiichi Sankyo Company, Limited Dispiropyrrolidine derivatives
DK2691443T3 (en) 2011-03-28 2021-05-03 Massachusetts Inst Technology CONJUGIATED LIPOMERS AND USES OF THESE
CN102702066A (en) * 2011-03-28 2012-10-03 苏州百灵威超精细材料有限公司 Novel method for preparing intermediate 6-chloro-5-fluoroindole used for synthesizing anticancer and weight-reducing medicine
ES2624808T3 (en) 2011-05-11 2017-07-17 The Regents Of The University Of Michigan MDM2 spirooxindol antagonists
WO2012177927A1 (en) 2011-06-21 2012-12-27 Mayo Foundation For Medical Education And Research Transgenic animals capable of being induced to delete senescent cells
WO2012176123A1 (en) * 2011-06-22 2012-12-27 Novartis Ag 3 - imidazolyl- indoles for the treatment of proliferative diseases
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
US20140335074A1 (en) 2011-12-13 2014-11-13 Buck Institute For Research On Aging Methods for improving medical therapies
WO2013158664A2 (en) 2012-04-17 2013-10-24 Kythera Biopharmaceuticals, Inc. Use of engineered viruses to specifically kill senescent cells
CA2884870C (en) 2012-08-13 2022-03-29 Massachusetts Institute Of Technology Amine-containing lipidoids and uses thereof
US9901080B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells
US9901081B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse for determining the role of senescent cells in cancer
TWI586668B (en) 2012-09-06 2017-06-11 第一三共股份有限公司 Crystals of dispiropyrrolidine derivative
TW201429969A (en) 2012-12-20 2014-08-01 Merck Sharp & Dohme Substituted imidazolium as an HDM2 inhibitor
WO2014179562A1 (en) 2013-05-01 2014-11-06 Massachusetts Institute Of Technology 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
EP3669881B1 (en) 2014-01-28 2022-03-30 Buck Institute for Research on Aging Compositions for use in the treatment of senescence-assiocated eye disease and disorders
WO2015116735A1 (en) 2014-01-28 2015-08-06 Mayo Foundation For Medical Education And Research Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders
EP3139942B1 (en) 2014-05-05 2019-12-18 Bioventures, Llc COMPOSITIONS AND METHODS FOR INHIBITING ANTIAPOPTOTIC Bcl-2 PROTEINS AS ANTI-AGING AGENTS
US9840479B2 (en) 2014-07-02 2017-12-12 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
JP6503386B2 (en) 2014-07-03 2019-04-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Novel spiro [3H-indol-3,2'-pyrrolidine] -2 (1H) -one compounds and derivatives as MDM2-p53 inhibitors
US10071087B2 (en) 2014-07-22 2018-09-11 Bioventures, Llc Compositions and methods for selectively depleting senescent cells
KR20170042779A (en) 2014-08-21 2017-04-19 베링거 인겔하임 인터내셔날 게엠베하 New spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
US20180006236A1 (en) 2014-12-26 2018-01-04 Dow Global Technologies Llc Organic compounds and electronic device comprising organic layer comprising organic compounds
CA2976752C (en) 2015-02-20 2019-12-17 Daiichi Sankyo Company, Limited Method for treating cancer by combined use
TWI697329B (en) 2015-04-13 2020-07-01 日商第一三共股份有限公司 Medicament for use in the treatment of a hematological cancer and use thereof
WO2016207089A1 (en) 2015-06-22 2016-12-29 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups
JOP20160198B1 (en) * 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc Single or di-substituted indole derivatives as inhibitors of viral replication of fennel fever
PL3359542T3 (en) 2015-10-09 2021-09-20 Boehringer Ingelheim International Gmbh COMPOUNDS AND DERIVATIVES SPIRO [3H-INDOLO-3,2′-PYROLIDINE] -2 (1H) -ONE AS MDM2-P53 INHIBITORS
US10759808B2 (en) 2016-04-06 2020-09-01 The Regents Of The University Of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
CN109415336B (en) 2016-04-06 2023-08-29 密执安大学评议会 MDM2 protein degrader
JP6936498B2 (en) 2016-04-21 2021-09-15 バイオベンチャーズ・リミテッド・ライアビリティ・カンパニーＢｉｏＶｅｎｔｕｒｅｓ， ＬＬＣ Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and their use
CN105906610B (en) * 2016-05-24 2018-10-23 绍兴文理学院 A kind of 3-（4- phenyl -1H- imidazoles -5- bases）- 1H- indole derivatives and its preparation method and application
PT3272745T (en) * 2016-07-21 2019-09-27 Inst Farmakologii Polskiej Akademii Nauk Imidazolyl-substituted indole derivatives binding 5-ht7 serotonin receptor and pharmaceutical compositions thereof
KR20190068544A (en) 2016-10-17 2019-06-18 다이이찌 산쿄 가부시키가이샤 Combination treatment of MDM2 inhibitor with DNA methyltransferase inhibitor
TW201831477A (en) 2016-11-28 2018-09-01 瑞士商赫孚孟拉羅股份公司 Oxadiazolone transient receptor potential channel inhibitors
WO2018114578A1 (en) 2016-12-21 2018-06-28 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (adcs) having enzymatically cleavable groups
CN110461838B (en) 2017-03-07 2022-05-06 豪夫迈·罗氏有限公司 Oxadiazole Transient Receptor Potential Channel Inhibitors
BR112019021032A2 (en) 2017-04-05 2020-05-05 Boehringer Ingelheim International Gmbh anticancer combination therapy
JOP20190245A1 (en) 2017-04-20 2019-10-15 Novartis Ag Sustained release delivery systems comprising traceless linkers
EP3630109A4 (en) * 2017-05-26 2021-03-17 Rutgers, the State University of New Jersey Bacterial efflux pump inhibitors
JP7385284B2 (en) 2018-01-22 2023-11-22 バイオベンチャーズ・リミテッド・ライアビリティ・カンパニー BCL-2 proteolytic agents for cancer treatment
US10710994B2 (en) 2018-03-19 2020-07-14 Genentech, Inc. Oxadiazole transient receptor potential channel inhibitors
WO2019221755A1 (en) 2018-05-18 2019-11-21 Bioventures, Llc Piperlongumine analogues and uses thereof
AR116566A1 (en) 2018-10-03 2021-05-19 Novartis Ag SUSTAINED ADMINISTRATION OF ANGIOPOYETIN-SIMILAR POLIPEPTIDES 3
US12281099B2 (en) * 2019-02-26 2025-04-22 Boehringer Ingelheim International Gmbh Isoindolinone substituted indoles and derivatives as RAS inhibitors
US12186401B2 (en) 2019-03-01 2025-01-07 Ontario Institute for Cancer Research (OICR) and Sinai Health System Amide-based proteolysis modulators of B-rapidly accelerated fibrosarcoma (BRAF) and associated uses
WO2022137085A1 (en) * 2020-12-22 2022-06-30 Novartis Ag Indole derivatives useful in treating conditions associated with cgas
WO2022204235A1 (en) * 2021-03-23 2022-09-29 Nido Biosciences, Inc. Bicyclic compounds as androgen receptor modulators
CN117510416A (en) * 2023-11-06 2024-02-06 浙江普洛康裕制药有限公司 A kind of preparation method of (2R,5S)-4-Boc-2,5-dimethylpiperazine
PL447976A1 (en) * 2024-03-11 2025-09-15 Celon Pharma Spółka Akcyjna An imidazole-indole derivative that binds to the 5-HT7 serotonin receptor, a pharmaceutical composition containing the derivative, uses of the derivative and the composition, and an intermediate for preparing the imidazole-indole derivative
WO2025231011A1 (en) * 2024-05-01 2025-11-06 Omniab, Inc. Heteroarylindole inhibitors of apol-1

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19948417A1 (en) * 1999-10-07 2001-04-19 Morphochem Ag Imidazole derivatives and their use as medicines
JP2002114780A (en) * 2000-10-11 2002-04-16 Taisho Pharmaceut Co Ltd 4-(3-indolyl)imidazole derivative
CA2752738C (en) 2005-02-22 2014-05-27 The Regents Of The University Of Michigan Small molecule inhibitors of mdm2 and uses thereof
US7576082B2 (en) 2005-06-24 2009-08-18 Hoffman-La Roche Inc. Oxindole derivatives

Also Published As

Publication number Publication date
WO2008119741A3 (en) 2008-12-04
MA31260B1 (en) 2010-03-01
CN101679382A (en) 2010-03-24
US20100125064A1 (en) 2010-05-20
PA8774001A1 (en) 2008-11-19
DOP2009000229A (en) 2009-10-31
SMP200900085B (en) 2010-11-12
ZA200906210B (en) 2010-05-26
JP2010522723A (en) 2010-07-08
MX2009010413A (en) 2009-10-20
TN2009000388A1 (en) 2010-12-31
KR20090122403A (en) 2009-11-27
EP2142535A2 (en) 2010-01-13
TW200843746A (en) 2008-11-16
WO2008119741A2 (en) 2008-10-09
CA2682483A1 (en) 2008-10-09
CL2008000899A1 (en) 2009-02-20
AU2008234954B9 (en) 2012-02-02
AU2008234954B2 (en) 2011-10-27
ECSP099660A (en) 2009-10-30
US8053457B2 (en) 2011-11-08
AU2008234954A1 (en) 2008-10-09
AR065860A1 (en) 2009-07-08
CR11019A (en) 2009-10-20
BRPI0810082A2 (en) 2014-10-21
EA200901212A1 (en) 2010-04-30
GT200900256A (en) 2010-03-15
SMAP200900085A (en) 2010-01-19
PE20081897A1 (en) 2009-02-09
NI200900177A (en) 2010-09-09
IL200862A0 (en) 2010-05-17

Similar Documents

Publication Publication Date Title
UY30987A1 (en) 3-IMIDAZOLIL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES
CR11284A (en) SULFONAMIDS AS TRPM8 MODULATORS
UY32937A (en) COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY
NI201200029A (en) COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
ECSP11011079A (en) NEW HYDROXYARENE COMPOUNDS.
CO6670575A2 (en) Substituted aminopyrazoloqinazolines, useful in the treatment of proliferative diseases and pharmaceutical compositions that continue them
ECSP12011908A (en) OCTAHIDROPIRROLO [3,4-c] PIRROLOS DISUSTITUIDOS AS
BRPI0808775A2 (en) compounds and compositions as modulators of gpr119 activity
MX386545B (en) LEUKOCIDINS OF STAPHYLOCOCCUS AUREUS, THERAPEUTIC COMPOSITIONS AND USES THEREOF.
UY31705A1 (en) DERIVATIVES OF AZETIDINE AND CYCLLOBUTANE AS JAK INHIBITORS
ECSP11010949A (en) INHIBITORS OF CINASE PROTEIN ENZYMES ACTIVATED BY MITOGEN P38
MX2013001970A (en) PIRROLOPIRIMIDINE COMPOUNDS AND USES OF THE SAME.
CU24087B1 (en) CARBAZOL COMPOUNDS
UY32809A (en) COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CINASA S AND K
DOP2009000190A (en) TRICYCLE COMPOUNDS AND THEIR USE AS GLUCOCORTICOID RECEPTOR MODULATORS
PE20151023A1 (en) TRIAZOLOPYRAZINES
ECSP13013048A (en) SPIRO- [1,3] -OXACINES AND SPIRO- [1,4] -OXACEPINS AS INHIBITORS
ECSP078060A (en) 2,4-DIAMINO-PYRIMIDINS AS AURORA INHIBITORS
CR20110230A (en) INHIBITORS OF PROTEIN CINASE ENZYMES ACTIVATED BY MYTHOGEN P38
PA8842101A1 (en) HETEROARILOS SUBSTITUTED
MX2014010625A (en) Inhibitors of beta-secretase.
CR10060A (en) 3-AMINOCICLOPENTANOCARBOXAMIDS AS CHEMIOKIN RECEPTORS MODULATORS
CR20150067A (en) PIRCHES REPLACED AS BLOCKERS OF CALCIUM CHANNEL TYPE N
CR11423A (en) NEW SSH INHIBITORS AND THEIR USE
UY31016A1 (en) NEW NITROGEN HETEROCICLIC COMPOUNDS, ITS PREPARATION AND ITS USE AS ANTIBACTERIAL MEDICINES

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20170919